SynthesisIrish journal of medical science2016
Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials.
Synthesis in Irish journal of medical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04855513 (Prevention of Pre-eclampsia Using Metformin), which is not on this map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Effectiveness of antidiabetic agents for treatment of gestational diabetes: A methodological quality assessment of meta-analyses and network meta-analysis.Journal of diabetes investigation · 2021Pooled it
- Impact of metformin treatment during pregnancy on maternal outcomes: a systematic review/meta-analysis.Scientific reports · 2021Pooled it
- Pooled it
- Effectiveness of Metformin in the Prevention of Gestational Diabetes Mellitus in Obese Pregnant Women.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2018Trial
- Metformin for prevention of cesarean delivery and large-for-gestational-age newborns in non-diabetic obese pregnant women: a randomized clinical trial.Archives of endocrinology and metabolism · on this mapTrial
- Metformin for Treating Gestational Diabetes: What Have We Learned During the Last Two Decades? A Systematic Review.Life (Basel, Switzerland) · 2025Review
- Comparison of neonatal and maternal outcomes of anti-diabetic drugs in the treatment of gestational diabetes mellitus: Findings from Bayesian network meta-analysis.Journal of family medicine and primary care · 2022Review
- Prevention of Hypertensive Disorders of Pregnancy-Is There a Place for Metformin?Journal of clinical medicine · 2021Review
- Progress of Clinical Trials for the Treatment of Gestational Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Review
- Metformin in the management of diabetes during pregnancy and lactation.Drugs in context · 2018Review
- Comparative efficacy and safety of oral antidiabetic drugs and insulin in treating gestational diabetes mellitus: An updated PRISMA-compliant network meta-analysis.Medicine · 2017 · on this mapArticle
- The effects of prenatal metformin on obesogenic diet-induced alterations in maternal and fetal fatty acid metabolism.Nutrition & metabolism · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetformin is widely used in treatment of type 2 diabetes. However, whether it is safe for use in pregnancy is controversial.
methodsA search for relevant studies were performed using PubMed (1948-2014), Embase (1974-2014), the Web of knowledge (1950-2014), and the Cochrane database, included all randomized control trials published in English.
resultsEight RCTs (1712 patients with gestational diabetes mellitus) were retrieved; of those 853 patients were given metformin, and 859 patients were given insulin. Our results showed that metformin does not increase risk of prematurity (RR = 1.26; 95 % CI [0.89, 1.79], P = 0.19). In addition, metformin can either decrease the total weight gain [MD = -1.49, 95 % CI (-2.66, -0.31), P = 0.01] or weight gain after randomization [MD = -1.23, 95 % CI (-1.75, -0.71), P < 0.00001]. No significant differences were observed in patients with pre-eclampsia [RR = 0.82, 95 % CI (0.56, 1.2), P = 0.32] or caesarean section [RR = 0.93, 95 % CI (0.75, 1.16), P = 0.53]. Use of metformin also significantly decreased the risk of neonatal hypoglycemia [RR = 0.58, 95 % CI (0.43, 0.78), P = 0.0003] and admission rates to neonatal intensive care units [RR = 0.74, 95 % CI (0.61, 0.89), P = 0.002]. No other adverse effects were observed, such as hyperbilirubinaemia [RR = 0.83, 95 % CI (0.64, 1.08), P = 0.16], large for gestational age [RR = 0.85, 95 % CI (0.68, 1.05), P = 0.14], small for gestational age [RR = 0.92, 95 % CI (0.61, 1.39), P = 0.69], macrosomia [RR = 0.75, 95 % CI (0.54, 1.03), P = 0.07] or respiratory distress syndrome [RR = 0.88, 95 % CI (0.55, 1.41), P = 0.6].
conclusionsMetformin may be beneficial in treating gestational diabetes. However, even more studies are needed to provide more evidence for the future use of metformin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.